Summary

Report Details

The Retinal Gene Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Inherited Retinal Diseases, Clinical Trial Success and Approvals Driving Market Growth

Some of the key factors driving the retinal gene therapy market growth include increasing prevalence of inherited retinal diseases, success of the clinical trials & approvals, and advancements in gene therapy technologies. Inherited retinal diseases though small in concentration have been increasingly identified across regions. Therefore, growing prevalence of IRDs, including as retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) has led to the demand for effective therapies. In addition to this, gene therapy technology has been proving to be effective method for number of conditions including ocular diseases. Also, with significant players including clinical trial companies have witnessed success in the product development and having strong product pipeline is likely to boost the adoption of the gene therapy practices for retinal diseases. There have been continuous efforts including vector design, gene editing, non-invasive route of administration, and others have promised safety and efficacy of retinal gene therapy technology.

On the other hand, with success of the clinical trials, there has been significant investments from government and private stakeholders in research & development activities for retinal gene therapy. This will be very critical development in terms of continuous efforts towards development of effective gene therapies for rare retinal diseases.

Limited Treatment Reach and High Cost Likely to Hamper Industry Growth

As of now retinal gene therapy has been restricted to limited centres around the world that are effectively engaging in the gene therapy practices. The therapy has been gaining wider recognition in developed regions including North America and Europe. Therefore, this therapy has long strides to cover in terms of the adoption, development of expertise, and infrastructure. Also, the cost of retinal gene therapy is on the higher side considerably with patented products and initial phase of the product life cycle. Therefore, easy patient access to this novel therapy is difficult on the current scenario. This is subjected to change with wider recognition and insurance coverage for the treatment.

What Questions Should You Ask before Buying a Market Research Report?

• How is the retinal gene therapy market evolving?
• What is driving and restraining the retinal gene therapy market?
• How will each retinal gene therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each retinal gene therapy submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading retinal gene therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the retinal gene therapy projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of retinal gene therapy projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Retinal Gene Therapy market?
• Where is the retinal gene therapy market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Retinal Gene Therapy market today, and over the next 10 years:

• Our 235-page report provides 99 tables and 160 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Retinal Gene Therapy prices and recent developments.

Segments Covered in the Report

Approach

• Gene Replacement
• Gene Silencing
• Gene Editing
• Modifier Gene Therapy
• Others

Gene Therapy Vectors

• Viral Vectors
• Non-viral Vectors

Route of Administration

• Invasive
• Non-invasive

Indication

• Leber Congenital Amaurosis (LCA)
• Stargardt Disease
• Choroideremia
• X-linked Retinitis Pigmentosa (RP)
• Others

End-users

• Hospitals
• Academic & Research Institutes
• Ophthalmic Clinics
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Indonesia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Retinal Gene Therapy Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• AbbVie Inc.
• Adverum Biotechnologies, Inc.
• Beacon Therapeutics
• GenSight Biologics S.A.
• Hemera Biosciences LLC
• MeiraGTx Limited
• Novartis AG
• Oxford Biomedica PLC
• Oxular Limited
• PulseSight Therapeutics
• REGENXBIO Inc.
• Spark Therapeutics

Overall world revenue for Retinal Gene Therapy Market, 2024 to 2034 in terms of value the market will surpass US$110.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Retinal Gene Therapy Market, 2024 to 2034 report help you?

In summary, our 230+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Retinal Gene Therapy Market, 2024 to 2034, with forecasts for approach, gene therapy vectors, ocular route of administration, indication (global), end user, and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 22 key national markets – See forecasts for the Retinal Gene Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 12 of the major companies involved in the Retinal Gene Therapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Retinal Gene Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Retinal Gene Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Prevalence of Inherited Retinal Diseases (IRDs)
3.3.1.2 Advancements in Gene Therapy Technologies
3.3.1.3 Clinical Success and Regulatory Approvals
3.3.1.4 Growing Investment and Funding
3.3.2 Market Restraining Factors
3.3.2.1 Safety Concerns
3.3.2.2 Limited Treatment Reach
3.3.2.3 Long-Term Efficacy and Durability
3.3.2.4 High Cost of Treatment
3.3.2.5 Regulatory Challenges
3.3.3 Market Opportunities
3.3.3.1 Diversification of Targeted Diseases
3.3.3.2 Combination Therapies
3.3.3.3 Precision Medicine Approaches
3.3.3.4 Gene Editing Technologies
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.6 Pricing Analysis
3.7 Patient Data
3.8 Regulatory Framework
3.9 Emerging Markets and Megatrends

4 Retinal Gene Therapy Market Analysis by Approach
4.1 Key Findings
4.2 Retinal Gene Therapy Market Size Estimation and Forecast by Approach
4.3 Gene Replacement
4.3.1 Gene Replacement by Region, 2024-2034 (%)
4.3.2 Gene Replacement Market Share by Region, 2024 & 2034 (%)
4.4 Gene Silencing
4.4.1 Gene Silencing by Region, 2024-2034 (%)
4.4.2 Gene Silencing Market Share by Region, 2024 & 2034 (%)
4.5 Gene Editing
4.5.1 Gene Editing by Region, 2024-2034 (US$ Million)
4.5.2 Gene Editing Market Share by Region, 2024 & 2034 (%)
4.6 Modifier Gene Therapy
4.6.1 Modifier Gene Therapy by Region, 2024-2034 (US$ Million)
4.6.2 Modifier Gene Therapy Market Share by Region, 2024 & 2034 (%)
4.7 Others (Approach)
4.7.1 Others (Approach) by Region, 2024-2034 (US$ Million)
4.7.2 Others (Approach) Market Share by Region, 2024 & 2034 (%)

5 Retinal Gene Therapy Market Analysis by Gene Therapy Vectors
5.1 Key Findings
5.2 Gene Therapy Vectors: Market Attractiveness Index
5.3 Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
5.4 Viral Vectors
5.4.1 Viral Vectors Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Viral Vectors Market Share by Region, 2024 & 2034 (%)
5.5 Non-viral Vectors
5.5.1 Non-viral Vectors Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Non-viral Vectors Market Share by Region, 2024 & 2034 (%)

6 Retinal Gene Therapy Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration: Market Attractiveness Index
6.3 Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
6.4 Invasive
6.4.1 Invasive Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Invasive Market Share by Region, 2024 & 2034 (%)
6.5 Non-invasive
6.5.1 Non-invasive Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Non-invasive Market Share by Region, 2024 & 2034 (%)

7 Retinal Gene Therapy Market Analysis: By Indication
7.1 Key Findings
7.2 Indication Segment: Market Attractiveness Index
7.3 Retinal Gene Therapy Market Size Estimation and Forecast by Indication
7.4 Leber Congenital Amaurosis (LCA)
7.5 Stargardt Disease
7.6 Choroideremia
7.7 X-linked Retinitis Pigmentosa (RP)
7.8 Others

8 Retinal Gene Therapy Market Analysis: End-users
8.1 Key Findings
8.2 End-users Segment: Market Attractiveness Index
8.3 Retinal Gene Therapy Market Segment Size Estimation and Forecast by End-users
8.4 Hospitals
8.4.1 Hospital Market Size by Region, 2024-2034 (US$ Million)
8.4.2 Hospitals Market Share by Region, 2024 & 2034 (%)
8.5 Academic & Research Institutes
8.5.1 Academic & Research Market Size by Region, 2024-2034 (US$ Million)
8.5.2 Academic & Research Institutes Market Share by Region, 2024 & 2034 (%)
8.6 Ophthalmic Clinics
8.6.1 Ophthalmic Clinics Market Size by Region, 2024-2034 (US$ Million)
8.6.2 Ophthalmic Clinics Market Share by Region, 2024 & 2034 (%)
8.7 Others
8.7.1 Others Market Size by Region, 2024-2034 (US$ Million)
8.7.2 Other Market Share by Region, 2024 & 2034 (%)

9 Retinal Gene Therapy Market Analysis by Region
9.1 Key Findings
9.2 Retinal Gene Therapy by Region: Market Attractiveness Index
9.3 Regional Market Size Estimation and Forecast

10 North America Retinal Gene Therapy Market Analysis
10.1 Key Findings
10.2 North America Retinal Gene Therapy Market Attractiveness Index
10.3 North America Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 North America Retinal Gene Therapy Market Size Estimation and Forecast by Country
10.5 North America Retinal Gene Therapy Market Size Estimation and Forecast by Approach
10.6 North America Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
10.7 North America Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
10.8 North America Retinal Gene Therapy Market Size Estimation and Forecast by End-users
10.9 U.S. Retinal Gene Therapy Market Analysis
10.10 Canada Retinal Gene Therapy Market Analysis

11 Europe Retinal Gene Therapy Market Analysis
11.1 Key Findings
11.2 Europe Retinal Gene Therapy Market Attractiveness Index
11.3 Europe Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Country
11.5 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Approach
11.6 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
11.7 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
11.8 Europe Retinal Gene Therapy Market Size Estimation and Forecast by End-users
11.9 Germany Retinal Gene Therapy Market Analysis
11.10 France Retinal Gene Therapy Market Analysis
11.11 UK Retinal Gene Therapy Market Analysis
11.12 Italy Retinal Gene Therapy Market Analysis
11.13 Spain Retinal Gene Therapy Market Analysis
11.14 Russia Retinal Gene Therapy Market Analysis
11.15 Rest of Europe Retinal Gene Therapy Market Analysis

12 Asia Pacific Retinal Gene Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific Retinal Gene Therapy Market Attractiveness Index
12.3 Asia Pacific Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Approach
12.6 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
12.7 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
12.8 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by End-users
12.9 Japan Retinal Gene Therapy Market Analysis
12.10 China Retinal Gene Therapy Market Analysis
12.11 India Retinal Gene Therapy Market Analysis
12.12 Australia Retinal Gene Therapy Market Analysis
12.13 South Korea Retinal Gene Therapy Market Analysis
12.14 Indonesia Retinal Gene Therapy Market Analysis
12.15 Rest of Asia Pacific Retinal Gene Therapy Market Analysis

13 Latin America Retinal Gene Therapy Market Analysis
13.1 Key Findings
13.2 Latin America Retinal Gene Therapy Market Attractiveness Index
13.3 Latin America Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Country
13.5 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Approach
13.6 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
13.7 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
13.8 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by End-users
13.9 Brazil Retinal Gene Therapy Market Analysis
13.10 Mexico Retinal Gene Therapy Market Analysis
13.11 Rest of Latin America Retinal Gene Therapy Market Analysis

14 MEA Retinal Gene Therapy Market Analysis
14.1 Key Findings
14.2 MEA Retinal Gene Therapy Market Attractiveness Index
14.3 MEA Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Country
14.5 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Approach
14.6 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
14.7 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
14.8 MEA Retinal Gene Therapy Market Size Estimation and Forecast by End-users
14.9 GCC Retinal Gene Therapy Market Analysis
14.10 South Africa Retinal Gene Therapy Market Analysis
14.11 Rest of MEA Retinal Gene Therapy Market Analysis

15 Company Profiles
15.1 Competitive Landscape, 2023
15.2 Strategic Outlook
15.3 Novartis AG
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2019-2023
15.3.3.2 R&D, 2019-2023
15.3.3.3 Regional Market Shares, 2023
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.3.6 SWOT Analysis
15.4 Beacon Therapeutics
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.4.4 Clinical Trials
15.4.5 Strategic Outlook
15.4.6 SWOT Analysis
15.5 Spark Therapeutics
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Product Benchmarking
15.5.4 Clinical Trials
15.5.5 Strategic Outlook
15.5.6 SWOT Analysis
15.6 Adverum Biotechnologies, Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.6.4 Clinical Trials
15.6.5 SWOT Analysis
15.7 REGENXBIO Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2018-2023
15.7.3.2 R&D, 2018-2023
15.7.4 Product Benchmarking
15.7.5 Clinical Trials
15.7.6 SWOT Analysis
15.8 MeiraGTx Limited
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2018-2023
15.8.3.2 R&D, 2018-2023
15.8.4 Clinical Trials
15.8.5 SWOT Analysis
15.9 GenSight Biologics
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2020-2023
15.9.3.2 R&D, 2020-2023
15.9.4 Clinical Trials
15.9.5 SWOT Analysis
15.10 AbbVie Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2018-2023
15.10.3.2 R&D, 2018-2023
15.10.4 Clinical Trials
15.10.5 SWOT Analysis
15.11 Oxular Limited
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Clinical Trials
15.12 PulseSight Therapeutics
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Clinical Trials
15.12.4 SWOT Analysis
15.13 Oxford Biomedica PLC
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2019-2023
15.13.4 Product Benchmarking
15.13.5 SWOT Analysis
15.14 Hemera Biosciences LLC
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Clinical Trials

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Retinal Gene Therapy Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 3 Gene Replacement by Region, 2024-2034 (%, AGR%, CAGR%)
Table 4 Gene Silencing by Region, 2024-2034 (%, AGR%, CAGR%)
Table 5 Gene Editing by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 6 Modifier Gene Therapy by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 7 Others (Approach) by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 8 Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 9 Viral Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 10 Non-viral Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 11 Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 12 Invasive Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 13 Non-invasive Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 14 Retinal Gene Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 15 Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 16 Hospital Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 17 Academic & Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 18 Ophthalmic Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Retinal Gene Therapy Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 21 North America Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 22 North America Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 23 North America Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 North America Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 25 North America Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 26 U.S. Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 Canada Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 28 Europe Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 29 Europe Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 30 Europe Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 31 Europe Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 32 Europe Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 33 Germany Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 France Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 UK Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 36 Italy Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 37 Spain Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 38 Russia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 39 Rest of Europe Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 Asia Pacific Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 41 Asia Pacific Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Asia Pacific Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 43 Asia Pacific Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Asia Pacific Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 45 Japan Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 China Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 India Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 48 Australia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 South Korea Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 50 Indonesia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Asia Pacific Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 52 Latin America Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 Latin America Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 54 Latin America Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 55 Latin America Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 56 Latin America Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 57 Brazil Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 58 Mexico Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 59 Rest of Latin America Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 60 MEA Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 61 MEA Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 62 MEA Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 63 MEA Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 64 MEA Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 65 GCC Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 66 South Africa Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 67 Rest of MEA Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 68 Strategic Outlook
Table 69 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Novartis AG: Product Benchmarking
Table 71 Novartis AG: Strategic Outlook
Table 72 Beacon Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Beacon Therapeutics: Product Benchmarking
Table 74 Beacon Therapeutics: Clinical Trials
Table 75 Beacon Therapeutics: Strategic Outlook
Table 76 Spark Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Spark Therapeutics: Product Benchmarking
Table 78 Spark Therapeutics: Clinical Trials
Table 79 Spark Therapeutics: Strategic Outlook
Table 80 Adverum Biotechnologies, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Adverum Biotechnologies: Product Benchmarking
Table 82 Advernum Biotechnologies: Clinical Trials
Table 83 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 REGENXBIO Inc.: Product Benchmarking
Table 85 REGENXBIO Inc.: Clinical Trials
Table 86 MeiraGTx Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 MeiraGTx Limited: Clinical Trials
Table 88 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 GenSight Biologics: Clinical Trials
Table 90 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 AbbVie Inc.: Clinical Trials
Table 92 Oxular Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Oxular Limited.: Clinical Trials
Table 94 PulseSight Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 PulseSight Therapeutics: Clinical Trials
Table 96 Oxford Biomedica PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Oxford Biomedica PLC.: Product Benchmarking
Table 98 Hemera Biosciences LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Hemera Biosciences.: Clinical Trials
 
List of Figures
Figure 1 Retinal Gene Therapy Market Segmentation
Figure 2 Retinal Gene Therapy Market by Approach: Market Attractiveness Index
Figure 3 Retinal Gene Therapy Market by Gene Therapy Vectors: Market Attractiveness Index
Figure 4 Retinal Gene Therapy Market by Route of Administration: Market Attractiveness Index
Figure 5 Retinal Gene Therapy Market by Indication: Market Attractiveness Index
Figure 6 Retinal Gene Therapy Market by End-users: Market Attractiveness Index
Figure 7 Retinal Gene Therapy Market Attractiveness Index by Region
Figure 8 Retinal Gene Therapy Market: Market Dynamics
Figure 9 Retinal Gene Therapy Market: Impact Analysis
Figure 10 Retinal Gene Therapy Market: Porter’s Five Forces Analysis
Figure 11 Retinal Gene Therapy Market: PEST Analysis
Figure 12 Retinal Gene Therapy Market by Approach: Market Attractiveness Index
Figure 13 Retinal Gene Therapy Market Share Forecast by Approach, 2024, 2029, 2034 (%)
Figure 14 Gene Replacement by Region, 2024-2034 (US$ Million)
Figure 15 Gene Replacement Market Share Forecast by Region, 2024 & 2034 (%)
Figure 16 Gene Silencing by Region, 2024-2034 (US$ Million)
Figure 17 Gene Silencing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 18 Gene Editing by Region, 2024-2034 (US$ Million)
Figure 19 Gene Editing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Modifier Gene Therapy by Region, 2024-2034 (US$ Million)
Figure 21 Modifier Gene Therapy Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Others (Approach) by region, 2024-2034 (US$ Million)
Figure 23 Others (Approach) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Retinal Gene Therapy Market by Gene Therapy Vectors: Market Attractiveness Index
Figure 25 Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 26 Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024, 2029, 2034 (%)
Figure 27 Viral Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 28 Viral Vectors Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Non-viral Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 30 Non-viral Vectors Segment Market Forecast by Region, 2024-2034 (%)
Figure 31 Retinal Gene Therapy Market by Route of Administration: Market Attractiveness Index
Figure 32 Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 33 Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 34 Invasive Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 35 Invasive Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Non-invasive Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 37 Non-invasive Segment Market Forecast by Region, 2024-2034 (%)
Figure 38 Retinal Gene Therapy Market by Room Tariff: Market Attractiveness Index
Figure 39 Retinal Gene Therapy Market by Indication, 2024-2034 (US$ Million, AGR %)
Figure 40 Retinal Gene Therapy Market by Indication, 2024, 2029, 2034 (%)
Figure 41 End-users Segment: Market Attractiveness Index
Figure 42 End-users Segment Forecast, 2024-2034 (US$ Million, AGR %)
Figure 43 Retinal Gene Therapy Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 44 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Academic & Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Academic & Research Institutes Segment Market Forecast by Region, 2024-2034 (%)
Figure 48 Ophthalmic Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Ophthalmic Clinics Segment Market Forecast by Region, 2024-2034 (%)
Figure 50 Other Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 51 Others Segment Market Forecast by Region, 2024-2034 (%)
Figure 52 Global Retinal Gene Therapy by Region: Market Attractiveness Index
Figure 53 Retinal Gene Therapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 54 Retinal Gene Therapy Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 55 Retinal Gene Therapy Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 North America Retinal Gene Therapy Market Attractiveness Index
Figure 57 North America Retinal Gene Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 58 North America Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 59 North America Retinal Gene Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 60 North America Retinal Gene Therapy Market: Approach, 2024-2034 (%, AGR %)
Figure 61 North America Retinal Gene Therapy Market Share Forecast by Approach 2024, 2029, 2034 (%)
Figure 62 North America Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 63 North America Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024 & 2034 (%)
Figure 64 North America Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 65 North America Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 66 North America Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Retinal Gene Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 68 U.S. Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 69 Canada Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 70 Europe Retinal Gene Therapy Market Attractiveness Index
Figure 71 Europe Retinal Gene Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 72 Europe Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 73 Europe Retinal Gene Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 74 Europe Retinal Gene Therapy Market by Approach, 2024-2034 (US$ Million, AGR %)
Figure 75 Europe Retinal Gene Therapy Market Share Forecast by Approach 2024, 2029, 2034 (%)
Figure 76 Europe Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 77 Europe Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024 & 2034 (%)
Figure 78 Europe Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 79 Europe Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 80 Europe Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Retinal Gene Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 82 Germany Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 83 France Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 UK Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 85 Italy Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 86 Spain Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 Russia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 88 Rest of Europe Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 89 Asia Pacific Retinal Gene Therapy Market Attractiveness Index
Figure 90 Asia Pacific Retinal Gene Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 91 Asia Pacific Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 92 Asia Pacific Retinal Gene Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 93 Asia Pacific Retinal Gene Therapy Market: Approach, 2024-2034 (US$ Million, AGR %)
Figure 94 Asia Pacific Retinal Gene Therapy Market Share Forecast by Approach 2024, 2029, 2034 (%)
Figure 95 Asia Pacific Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 96 Asia Pacific Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024 & 2034 (%)
Figure 97 Asia Pacific Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 98 Asia Pacific Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 99 Asia Pacific Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 100 Asia Pacific Retinal Gene Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 101 Japan Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 102 China Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 India Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 104 Australia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 105 South Korea Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 Indonesia Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 107 Rest of Asia Pacific Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 108 Latin America Retinal Gene Therapy Market Attractiveness Index
Figure 109 North America Retinal Gene Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 110 Latin America Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 111 Latin America Retinal Gene Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 112 Latin America Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR %)
Figure 113 Latin America Retinal Gene Therapy Market Share Forecast by Approach 2024, 2029, 2034 (%)
Figure 114 Latin America Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 115 Latin America Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024 & 2034 (%)
Figure 116 Latin America Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 118 Latin America Retinal Gene Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 119 Latin America Retinal Gene Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 120 Brazil Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 121 Mexico Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 122 Rest of Latin America Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 MEA Retinal Gene Therapy Market Attractiveness Index
Figure 124 MEA Retinal Gene Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 125 MEA Retinal Gene Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 126 MEA Retinal Gene Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 127 MEA Retinal Gene Therapy Market Forecast by Approach, 2024-2034 (US$ Million, AGR %)
Figure 128 Latin America Retinal Gene Therapy Market Share Forecast by Approach 2024, 2029, 2034 (%)
Figure 129 MEA Retinal Gene Therapy Market Forecast by Gene Therapy Vectors, 2024-2034 (US$ Million, AGR %)
Figure 130 MEA Retinal Gene Therapy Market Share Forecast by Gene Therapy Vectors, 2024 & 2034 (%)
Figure 131 MEA Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 132 MEA Retinal Gene Therapy Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 133 MEA Retinal Gene Therapy Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
Figure 134 MEA Retinal Gene Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 135 GCC Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 136 South Africa Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 137 Rest of MEA Retinal Gene Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 138 Retinal Gene Therapy Market: Company Share/Ranking, 2023
Figure 139 Novartis AG: Net Revenue, 2019-2023 (US$ Billion, AGR%)
Figure 140 Novartis AG: R&D, 2019-2023 (US$ Billion, AGR%)
Figure 141 Novartis AG: Regional Market Shares, 2023 (%)
Figure 142 Novartis AG: SWOT Analysis
Figure 143 Beacon Therapeutics: SWOT Analysis
Figure 144 Spark Therapeutics: SWOT Analysis
Figure 145 Adverum Biotechnologies, Inc.: SWOT Analysis
Figure 146 REGENXBIO Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 147 REGENXBIO Inc.: R&D, 2018-2023 (US$ Million, AGR %)
Figure 148 REGENXBIO Inc.: SWOT Analysis
Figure 149 MeiraGTx Limited.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 150 MeiraGTx Limited: R&D, 2018-2023 (US$ Million, AGR %)
Figure 151 MeiraGTx Limited: SWOT Analysis
Figure 152 GenSight Biologics: Net Revenue, 2020-2023 (US$ Million, AGR %)
Figure 153 GenSight Biologics: R&D, 2020-2023 (US$ Million, AGR %)
Figure 154 GenSight Biologics: SWOT Analysis
Figure 155 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Billion, AGR%)
Figure 156 AbbVie Inc.: R&D, 2018-2023 (US$ Billion, AGR%)
Figure 157 AbbVie Inc.: SWOT Analysis
Figure 158 PulseSight Therapeutics: SWOT Analysis
Figure 159 Oxford Biomedica PLC: Net Revenue, 2019-2023 (US$ Billion, AGR%)
Figure 160 Oxford Biomedica PLC: SWOT Analysis